Skip to main content

Table 1 Patient characteristics

From: Renin-angiotensin-aldosterone system blockers after KDIGO stage 3 acute kidney injury: use and impact on 2-year mortality in the AKIKI trial

 

ACEi/ARB +

(N = 45)

ACEi/ARB - (N = 303)

p

Characteristic at ICU admission

 Age—years

64.4 ± 15.1

63.1 ± 14.7

0.6

 Male sex—no. (%)

32 (71)

193 (63)

0.3

 Weight—kg

85.8 ± 23.7

82.4 ± 20.5

0.3

Main reason for ICU admission—no. (%)

 Medical

37 (82)

263 (87)

 

 Surgical, emergency

5 (11)

66 (22)

 

 Surgical, scheduled

3 (7)

19 (6)

 

Serum creatinine before ICU admission

92.0 ± 24.7

83.4 ± 24.0

0.03

Coexisting condition—no. (%)

 Chronic renal failure

6 (13)

26 (9)

0.3

 Hypertension

28 (62)

152 (50)

0.1

 Diabetes mellitus

3 (7)

31 (10)

0.67

 Congestive heart failure

6 (13)

17 (6)

0.05

 Ischemic heart disease

8 (18)

26 (9)

0.05

SAPS III at ICU admission

63.0 ± 14.0

68.3 ± 14.3

0.02

Septic shock—no. (%)

26 (58)

128 (42)

0.05

Biological characteristics

 Serum creatinine—µmol/L

203.9 (133.1)

219.6 (136.9)

0.47

 Blood urea nitrogen—mmol/L

13.0 (8.4)

14.4 (9.3)

0.34

 Serum potassium—mmol/L

4.1 (0.8)

4.3 (0.9)

0.37

 Serum bicarbonate—mmol/L

19.9 (5.0)

18.7 (5.7)

0.17

Characteristic of ICU stay

 Physiological support during ICU stay—no. (%)

  Invasive mechanical ventilation

41 (91)

260 (86)

0.33

  Vasopressor support (epinephrine or norepinephrine)

31 (69)

257 (85)

0.008

Number of patients who received RRT—no. (%)

28 (62)

211 (70)

0.32

Ventilator duration—median (IQR)

5 (5–13)

5 (4–10)

0.40

Vasopressor-free days—median (IQR)

3 (2–5)

4 (2–7)

0.11

Length of ICU stay—median (IQR)

18 (11–20)

15 (8–22)

0.35

RRT dependence—no. (%)

 At day 28

4 (9)

27 (9)

0.99

 At day 60

1 (2)

9 (3)

0.77

Mortality—no. (%[95% CI])

 At day 60

6 (13)

39 (12)

0.73

Creatinine at ICU discharge

183.6 ± 136.4

177.9 ± 150.1

0.81

  1. ACEi angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blockers, ICU intensive care unit, IQR interquartile range, RRT renal replacement therapy, CI confidence interval